Contract Research & Services
Contract Services

Contract Services White Papers

View white papers from other Pharmaceutical sectors:
1-15 of 79 results
THE FUTURE OF THE PHARMACEUTICAL INDUSTRY
| By NSF International
YOUR CHANCE TO CONTRIBUTE by Martin Lush Ever participated in one of those benchmarking exercises? You know what I mean. When a (usually) fresh-faced consultant asks lots of questions and fills in a spreadsheet comparing what you do with your competitors. Well, beware.
Contract Research & Services > Contract Services > White Papers
REVIEW OF EU ATMP GMP GUIDANCE
| By NSF International
On November 22, 2017, the EU Commission adopted the Guidelines on Good Manufacturing Practice specific to advanced therapy medicinal products (ATMPs), as Part IV of EudraLex Volume 4. These guidelines come into force on May 22, 2018. When these GMP guidelines for ATMPs were first drafted, most of the manufacturers of ATMPs were critical of the guidelines being a separate guidance document rather than being an annex to the existing guidelines in EudraLex Volume 4. There were also criticisms from smaller academic and hospital units that the new guidelines place too much burden on these units in their rigid application of industrial type GMPs, which they argued was not practicable to these highly innovative products. Concern was also expressed that as the initial draft stood, the innovative research that was going on with ATMPs would be hindered in the EU.
Contract Research & Services > Contract Services > White Papers
Data Integrity A Closer Look
| By NSF International
Data integrity remains a perennial hot topic impacting the pharma biotech industry and the trend has been picking up steam; the number of data integrity-related warning letters has increased consistently since 2010. A number of new guidance documents came out in 2016 by FDA, MHRA, EMA PIC/S and the WHO and yet companies continue to grapple with data integrity issues.
Contract Research & Services > Contract Services > White Papers
Hierarchy For Capa Effectiveness
| By NSF International
Have you ever reviewed an investigation report and wondered whether the proposed corrective and preventive action (CAPA) would be effective? Sometimes, we shrug our shoulders and say, “At least they put something in place”. We all know that the FDA expects us to include an effectiveness check, but do we have enough guidance to make these checks meaningful? NSF suggests that you consider these three questions: 1. What will you measure? 2. When will you measure it? 3. What is your acceptance standard?
Contract Research & Services > Contract Services > White Papers
Is Fear of Risk Your Biggest Risk?
| By NSF International
In this white paper, NSF International's Martin Lush gives his insights into the pharmaceutical industry's relationship with risk. It includes five steps to help you become risk smart.
Contract Research & Services > Contract Services > White Papers
Risk Assessment: A Closer Look
| By NSF International
NSF International’s Andy Barnett takes a deeper look into ICH Q9, Quality Risk Management, with particular focus on the failure mode and effects analysis tool for risk management.
Contract Research & Services > Contract Services > White Papers
Aging Facilities
| By NSF International
Aging facilities is a trendy catchphrase that has taken hold in the biopharmaceutical industry. This white paper by NSF International’s Nicholas Markel provides a few questions to determine if you have an aging facility as well as how to address any issues you may have.
Contract Research & Services > Contract Services > White Papers
NSF: Global Selection Considerations for CMO When Conducting Due Diligence
| By NSF International
Deciding to use a CMO requires a thorough due diligence exercise conducted both as desktop and on-site reviews. This NSF white paper by Maxine Fritz provides the fundamental factors to consider when engaging and deciding on a CMO.
Contract Research & Services > Contract Services > White Papers
NSF: Time To Move Beyond Mediocre CAPAs and Make Them More Effective
| By NSF International
Have you ever wondered why some of your CAPAs fail to achieve the desired improvement? Wouldn’t it be nice if there were a way to evaluate the CAPA before you implement it? NSF proposes the use of our CAPA hierarchy, which will help investigators select a CAPA that is most likely to deliver the desired outcome. Read the white paper for more information on the hierarchy and find out how else to use it.
Contract Research & Services > Contract Services > White Papers
Do you have a robust and compliant CAPA System?
| By NSF International
Pharma biotech companies around the globe are struggling to juggle numerous priorities and challenges. One of their biggest struggles is to effectively manage CAPAs.
Contract Research & Services > Contract Services > White Papers
How to write to Regulatory Agencies when things go wrong
| By NSF International
Your essential guidance on what to do next after you receive a less than positive regulator's audit report.
Contract Research & Services > Contract Services > White Papers
1-15 of 79 results